Silexion Therapeutics Ltd.SLXNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+17.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+17.9%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
1.6x
Solid growth
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 625.32% |
| 2023 | 60.83% |
| 2022 | -38.87% |
| 2021 | 381.94% |
| 2020 | 0.00% |